306298-15-7

Basic information

• Product Name: 4-Methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-Methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 306298-15-7
• Molecular Weight: 483.618
• Mol File: 306298-15-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-Methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester(306298-15-7)
• EPA Substance Registry System: 4-Methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester(306298-15-7)

Safety Data

• Hazardous Substances Data: 306298-15-7(Hazardous Substances Data)

Upstream product

• 306298-13-5 (S)-3-Methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 306298-14-6 (S)-2-Methyl-1-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazine 
• 75-16-1 methylmagnesium bromide 
• 306298-12-4 Methanesulfonic acid (R)-1-(4-trifluoromethyl-phenyl)-propyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 711-33-1 4-trifluoromethyl propiophenone 
• 67081-98-5 (R)-1-(4-(trifluoromethyl)phenyl)propan-1-ol 

Downstream Products

• 306298-16-8 (S)-2-Methyl-4-(4-methyl-piperidin-4-yl)-1-[(S)-1-(4-trifluoromethyl-phenyl)-propyl]-piperazine 

Relevant articles and documents

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl) carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S) -methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Sel

The nature and the size of the benzylic substituent are shown to be the key to controlling receptor selectivity (CCR5 vs M1, M2) and potency in the title compounds. Optimization of the lead benzylic methyl compound 3 led to the methoxymethyl analogue 30,